Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)
- Report Description Table of Contents
- FAQs
Scope of the Report
The report titled “Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)”, provides an in-depth analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of patients), by segments, etc.
The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis of diagnostics penetration and the regions such as the US with an addressable market opportunity for the diagnostics penetration.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the pulmonary embolism diagnostics market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The competition in the pulmonary embolism diagnostic market, especially V/Q scan is dominated by one big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by Lantheus Holdings, Inc. (Xe-133).
Further, key players of the global pulmonary thromboembolism diagnostic market Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective business strategies.
Country Coverage
- Developed Regions (Canada, Europe, Australia and Parts of Asia)
- The US
Company Coverage
- Cyclopharm
- Jubilant LifeSciences Limited
- Philips
- Siemens
Executive Summary
Venous Thromboembolism (VTE) is a type of blood clot that starts in the vein. Most commonly VTE starts in the legs of the patient, however, it could occur in any other part of the body also. There are two types of VTE: Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE).
The pulmonary embolism generally occurs due to DVTs or pelvic vein thrombosis.
Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a tendency to block a blood vessel in the lungs and hence damage them.
Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery, genetic blood clotting disorder or fracture of the hip or leg, etc. The onset of pulmonary embolism is depicted by shortness of breath, sudden chest pain and coughing blood. These symptoms are then followed by other symptoms such as flank pain, wheezing, cardiac murmur, etc.
There are different types of tests done to detect pulmonary embolism, however, Computed Tomography Pulmonary Angiogram (CTPA) is the gold standard for detecting pulmonary embolism. Another alternative test done to detect pulmonary embolism is Ventilation-Perfusion (V/Q) Scanning.
Since prevention is better than cure, a healthy lifestyle is most commonly prescribed to prevent pulmonary embolism. However, pulmonary embolism is managed majorly through intake of anticoagulants, thrombolytics, vena cava filter and compression stockings.
The global pulmonary embolism diagnostics market is anticipated to increase at a significant CAGR during the years 2017-2021. The pulmonary embolism diagnostic market is expected to increase due to growth in number of cancer patients, aging population, increase in per-capita healthcare expenditure, etc. Yet the market faces some challenges such as, prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of Novel Oral anticoagulants.